BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Small cell lung cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for small cell lung cancer: 1166 (384 sponsors; 120 newly posted in the last 180 days, 57 stopped in the last 180 days; 39 new-entrant sponsors). Momentum score 15.5, rank 41 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 7, Phase 1 254, Phase 2 397, Phase 3 250, Phase 4 6, N/A 86.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN84P3 31, P4 1, P2 23, NA 23, P1 658
Merck Sharp & Dohme LLC MRK33P3 20, NA 1, P2 1214
Sichuan Baili Pharmaceutical Co., Ltd.27P2 11, P3 10, P1 657
Bristol-Myers Squibb BMY25P3 9, P2 9, NA 3, P1 442
Amgen AMGN22P3 9, P1 8, P2 513
Akeso14P3 7, P2 722
Hoffmann-La Roche10P3 7, NA 1, P2 201
Daiichi Sankyo17P2 7, P3 6, P1 3, NA 121
Eli Lilly and Company LLY17P1 7, P2 3, P3 6, P4 112
AbbVie ABBV16P2 5, P3 6, P1 530
Qilu Pharmaceutical Co., Ltd.8P3 6, P2 1, P1 113
Pfizer PFE25P3 5, P1 8, P2 6, P4 3, NA 332
Jiangsu Hansoh Pharmaceutical Co., Ltd.15P3 5, P1 9, P2 133
Shanghai Henlius Biotech14P2 6, P1 3, P3 512
Shanghai JMT-Bio Inc.7P2 2, P3 501
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY12P2 8, P3 432
Allist Pharmaceuticals, Inc.8P3 4, P2 3, P1 103
GlaxoSmithKline7P2 2, P3 4, P1 120
Janssen Research & Development, LLC11NA 1, P2 5, P3 3, P1 205
Gilead Sciences GILD5P3 3, P2 200
Mirati Therapeutics Inc.5P2 2, P3 300
Changchun GeneScience Pharmaceutical Co., Ltd.3P3 301
Summit Therapeutics SMMT3P3 300
Boehringer Ingelheim13NA 2, P1 6, P2 3, P3 235
BioNTech SE BNTX8P2 5, P3 2, P1 100

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P1/P2Monte Rosa Therapeutics, Inc GLUENCT05546268 Study of Oral MRT-2359 in Selected Cancer PatientsNSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC active not recruiting174
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05924841 A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung CancerSmall Cell Lung Cancerrecruiting100
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06437509 A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung CancerExtensive-stage Small-cell Lung Cancerrecruiting66
2026-12 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06500026 A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)Small Cell Lung Canceractive not recruiting722
2026-12 est.P1/P2Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.NCT07136285 Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLCSCLC, Extensive Stagerecruiting27
2026-12-15 est.P1/P2PMV Pharmaceuticals, Inc PMVPNCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Crecruiting300
2026-12-18 est.P2/P3Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB ChairNCT07145333 Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide PolymorphismsSCLCactive not recruiting600
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P2Pfizer PFENCT04553133 PF-07104091 as a Single Agent and in Combination TherapySmall Cell Lung Cancer; Ovarian Cancer; Breast Canceractive not recruiting157
2026-12-31 est.P3Changchun GeneScience Pharmaceutical Co., Ltd.NCT06961201 Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the CacheExtensive-stage Small Cell Lung Cancer (ES-SCLC); The Pre-cachexia or Cachexia Patients Who Have Notnot yet recruiting94
2027-01 est.P1/P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07208773 A Study of YL201 and Ivonescimab (AK112) in Advanced Solid TumorsAdvanced Solid Tumors; Non Small Cell Lung Cancer; Small Cell Lung Cancerrecruiting260
2027-02-14 est.P1/P2Beijing BiotechNCT07480213 Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC; SCLC, Extensive Stagerecruiting60
2027-02-14 est.P1/P2Beijing BiotechNCT07744256 Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC; Extensive-stage SCLCrecruiting60

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-18 est.P2/P3Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB ChairNCT01064466 Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide PolymorphismsSmall Cell Lung Canceractive not recruiting600
2026-10-22 est.P2Shanghai Henlius BiotechNCT06812260 A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLCSCLC, Extensive Stageactive not recruiting26
2026-09-28P1/P2Novartis Pharmaceuticals NVSNCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationKRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Sterminated74
2026-09 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06469879 A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer PatientsSmall Cell Lung Cancer Limited Stageunknown358
2026-09 est.P1/P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05978284 Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaSmall Cell Lung Cancer; Neuroendocrine Carcinomarecruiting54
2026-08-20P3Hansoh BioMedical R&D CompanyNCT06498479 ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung CancerSmall Cell Lung Cancercompleted461
2026-08 est.P2Tasly Biopharmaceuticals Co., Ltd.NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid TumorsRecurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervicnot yet recruiting120
2026-08 est.P1/P2Jacobio Pharmaceuticals Co., Ltd.NCT05490472 JAB-2485 Activity in Adult Patients With Advanced Solid TumorsSolid Tumors; ER+ Breast Cancer; Triple Negative Breast Cancer, TNBC; ARID1A Gene Mutation; Small Cerecruiting102
2026-06-30 est.P3Shanghai Henlius BiotechNCT05353257 A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small CelLimited-Stage Small Cell Lung Canceractive not recruiting511

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "small cell lung cancer"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.